ArticleJournal of translational medicine2004
Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer.
Article in Journal of translational medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 161 citations in OpenAlex.
- Development of a Targeted Choroidal Injury Model for the Study of Retinal Degenerations and Therapeutic Cell Replacement.Translational vision science & technology · 2026Article
- CD133 Shapes Extracellular Vesicle Cargo and Angiogenic Function in Basal-Like Triple-Negative Breast Cancer.Journal of extracellular vesicles · 2026Article
- Stem Cells and their Key Derivatives in Degenerative Musculoskeletal Diseases.Stem cell reviews and reports · 2026Review
- Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies.Signal transduction and targeted therapy · 2025Review
- Plasma extracellular vesicles carry immune system-related peptides that predict human longevity.GeroScience · 2025Article
- Preeclampsia prediction and diagnosis: a comprehensive historical review from clinical insights to omics perspectives.Frontiers in medicine · 2025Review
- Article
- Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression.Cancer research · 2024Article
- Paracrine Responses of Cardiosphere-Derived Cells to Cytokines and TLR Ligands: A Comparative Analysis.International journal of molecular sciences · 2023Article
- Diaphragmatic hernia repair porcine model to compare the performance of biodegradable membranes against Gore-TexPediatric surgery international · 2023Article
- Circulating Extracellular Vesicles in Subarachnoid Hemorrhage Patients: Characterization and Cellular Effects.International journal of molecular sciences · 2023Article
- Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers.International journal of molecular sciences · 2023Review
- The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer.Journal of translational medicine · 2022Review
- High-precision tumor resection down to few-cell level guided by NIR-IIb molecular fluorescence imaging.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- The role of endoglin and its soluble form in pathogenesis of preeclampsia.Molecular and cellular biochemistry · 2022Review
- Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology.Oncoimmunology · 2022Article
- The Effects of Cryogenic Storage on Human Dental Pulp Stem Cells.International journal of molecular sciences · 2021Article
- Cross-Link-Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2020Article
- Assessment of Tumor Angiogenesis by Expression of CD 105 in Ameloblastoma, Odontogenic Keratocyst and Central Giant Cell Lesion.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- CD105 is a prognostic marker and valid endothelial target for microbubble platforms in cholangiocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2020Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.